The children studied developed virus-fighting antibodies similar to the levels vaccinated adults received from a full dose.
According to a recent news release from Moderna, studies have shown that children ages 6 to 11 have strong immune responses to the company's kid-size COVID-19 vaccination, which offered young children half the normal dose given to adults with positive results.
Moderna tested two child-sized doses a month apart, and found the children developed virus-fighting antibodies similar to the levels vaccinated adults received from a full dose, Moderna said in a release., in offering vaccines to younger children soon. Pfizer's vaccination is already authorized for anyone 12 or older, but the company is currently seeking to expand distribution to younger children.
The study was too small to spot any extremely rare side effects, such as heart inflammation that sometimes occurs after either the Moderna or Pfizer vaccines, mostly among young men.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Moderna Data Shows Covid-19 Vaccine Produced Strong Immune Response in 6- to 11-Year-OldsModerna said it would submit the results from an interim study to health regulators in the U.S., Europe and elsewhere in seeking authorization for 6- to 11-year-olds.
続きを読む »
Moderna says its Covid-19 vaccine was well-tolerated and generated robust immune response in children ages 6 to 11Interim results of a Phase 2/3 trial showed Moderna's Covid-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said Monday.
続きを読む »
Moderna says its Covid vaccine has strong results in children ages 6 to 11Data from an interim study showed two 50 microgram doses of the vaccine, half the strength of the doses used in the vaccine given to adults, generated virus-neutralizing antibodies in children.
続きを読む »
Moderna says its COVID-19 vaccine is protective, safe in kids 6 to 11Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.
続きを読む »
Moderna Says Vaccine Safe, Effective in Kids 6 to 11Moderna announced its COVID-19 vaccine triggers a strong immune response in children ages 6 to 11, and the vaccine appears safe for the age group, comparable to the boost reported previously in teenagers and adults.
続きを読む »